Cytosorbents Corporation (CTSO)
- Previous Close
0.8020 - Open
0.8421 - Bid 0.7750 x 100
- Ask 0.8626 x 100
- Day's Range
0.7941 - 0.8625 - 52 Week Range
0.7820 - 4.2900 - Volume
97,610 - Avg. Volume
102,985 - Market Cap (intraday)
43.988M - Beta (5Y Monthly) 0.59
- PE Ratio (TTM)
-- - EPS (TTM)
-0.6400 - Earnings Date Apr 30, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.70
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
www.cytosorbents.comRecent News: CTSO
Performance Overview: CTSO
Trailing total returns as of 4/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CTSO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CTSO
Valuation Measures
Market Cap
44.24M
Enterprise Value
48.43M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.17
Price/Book (mrq)
1.90
Enterprise Value/Revenue
1.56
Enterprise Value/EBITDA
-1.66
Financial Highlights
Profitability and Income Statement
Profit Margin
-78.43%
Return on Assets (ttm)
-32.48%
Return on Equity (ttm)
-97.21%
Revenue (ttm)
36.35M
Net Income Avi to Common (ttm)
-28.51M
Diluted EPS (ttm)
-0.6400
Balance Sheet and Cash Flow
Total Cash (mrq)
14.13M
Total Debt/Equity (mrq)
78.68%
Levered Free Cash Flow (ttm)
-12.12M